25 XP   0   0   10

GeneReach Biotechnology
Buy, Hold or Sell?

Let's analyse Genereach together

PenkeI guess you are interested in GeneReach Biotechnology. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of GeneReach Biotechnology. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about GeneReach Biotechnology

I send you an email if I find something interesting about GeneReach Biotechnology.

Quick analysis of Genereach (30 sec.)










What can you expect buying and holding a share of Genereach? (30 sec.)

How much money do you get?

How much money do you get?
NT$0.00
When do you have the money?
1 year
How often do you get paid?
28.6%

What is your share worth?

Current worth
NT$15.01
Expected worth in 1 year
NT$10.83
How sure are you?
57.1%

+ What do you gain per year?

Total Gains per Share
NT$-4.18
Return On Investment
-13.1%

For what price can you sell your share?

Current Price per Share
NT$31.95
Expected price per share
NT$29.20 - NT$36.30
How sure are you?
50%

1. Valuation of Genereach (5 min.)




Live pricePrice per Share (EOD)

NT$31.95

Intrinsic Value Per Share

NT$-3.30 - NT$-5.45

Total Value Per Share

NT$11.71 - NT$9.56

2. Growth of Genereach (5 min.)




Is Genereach growing?

Current yearPrevious yearGrowGrow %
How rich?$26.4m$36.6m-$7.4m-25.6%

How much money is Genereach making?

Current yearPrevious yearGrowGrow %
Making money-$1.2m$1.6m-$2.9m-233.1%
Net Profit Margin-74.3%14.5%--

How much money comes from the company's main activities?

3. Financial Health of Genereach (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#542 / 1010

Most Revenue
#454 / 1010

Most Profit
#260 / 1010

Most Efficient
#547 / 1010

What can you expect buying and holding a share of Genereach? (5 min.)

Welcome investor! Genereach's management wants to use your money to grow the business. In return you get a share of Genereach.

What can you expect buying and holding a share of Genereach?

First you should know what it really means to hold a share of Genereach. And how you can make/lose money.

Speculation

The Price per Share of Genereach is NT$31.95. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Genereach.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Genereach, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is NT$15.01. Based on the TTM, the Book Value Change Per Share is NT$-1.05 per quarter. Based on the YOY, the Book Value Change Per Share is NT$0.06 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is NT$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Genereach.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 NT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per Share
Usd Eps-0.03-0.1%-0.02-0.1%0.030.1%0.020.1%0.020.1%
Usd Book Value Change Per Share-0.03-0.1%-0.03-0.1%0.000.0%0.030.1%0.030.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.020.1%0.020.1%
Usd Total Gains Per Share-0.03-0.1%-0.03-0.1%0.000.0%0.050.2%0.050.2%
Usd Price Per Share1.21-1.44-2.35-2.74-2.74-
Price to Earnings Ratio-9.73--17.36-4.68-5.52-5.52-
Price-to-Total Gains Ratio-36.87--60.33-0.25--0.04--0.04-
Price to Book Ratio2.63-2.81-3.67-5.21-5.21-
Price-to-Total Gains Ratio-36.87--60.33-0.25--0.04--0.04-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.980865
Number of shares1019
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.02
Usd Book Value Change Per Share-0.030.03
Usd Total Gains Per Share-0.030.05
Gains per Quarter (1019 shares)-32.7055.89
Gains per Year (1019 shares)-130.80223.56
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-131-14189134214
20-262-272179268438
30-392-403268402662
40-523-534358537886
50-654-6654476711110
60-785-7965368051334
70-916-9276269391558
80-1046-105871510731782
90-1177-118980512072006
100-1308-132089413422230

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%7.05.00.058.3%9.05.00.064.3%9.05.00.064.3%9.05.00.064.3%
Book Value Change Per Share0.04.00.00.0%5.07.00.041.7%7.07.00.050.0%7.07.00.050.0%7.07.00.050.0%
Dividend per Share0.00.04.00.0%4.00.08.033.3%4.00.010.028.6%4.00.010.028.6%4.00.010.028.6%
Total Gains per Share0.04.00.00.0%6.06.00.050.0%8.06.00.057.1%8.06.00.057.1%8.06.00.057.1%

Fundamentals of Genereach

About GeneReach Biotechnology

GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. The company offers automatic nucleic acid extraction systems, prep homogenization system, and mini centrifuge equipment; and reagents and consumables, comprising human IVD assays, iiPCR specific reagents, taco nucleic acid extraction reagents, IQ real quantitative systems, IQ2000 detection and prevention systems, and research reagents and consumables. The company also provides polymerase chain reaction training programs, molecular diagnostic technical solutions, laboratory installation services, OEM/ODM contract manufacturing services, and research collaboration services. It serves aquaculture, agriculture, food, and human health industries, as well as companion animals and livestock. GeneReach Biotechnology Corp. was founded in 2004 and is headquartered in Taichung, Taiwan.

Fundamental data was last updated by Penke on 2024-04-20 15:09:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is fair priced.

1.1. Profitability of GeneReach Biotechnology.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Genereach earns for each NT$1 of revenue.

  • Above 10% is considered healthy but always compare Genereach to the Biotechnology industry mean.
  • A Net Profit Margin of -106.2% means that NT$-1.06 for each NT$1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of GeneReach Biotechnology:

  • The MRQ is -106.2%. The company is making a huge loss. -2
  • The TTM is -74.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-106.2%TTM-74.3%-31.9%
TTM-74.3%YOY14.5%-88.8%
TTM-74.3%5Y-1.6%-72.6%
5Y-1.6%10Y-1.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-106.2%-207.2%+101.0%
TTM-74.3%-216.8%+142.5%
YOY14.5%-282.3%+296.8%
5Y-1.6%-436.8%+435.2%
10Y-1.6%-597.3%+595.7%
1.1.2. Return on Assets

Shows how efficient Genereach is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Genereach to the Biotechnology industry mean.
  • -4.9% Return on Assets means that Genereach generated NT$-0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of GeneReach Biotechnology:

  • The MRQ is -4.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -3.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-4.9%TTM-3.1%-1.8%
TTM-3.1%YOY2.8%-6.0%
TTM-3.1%5Y2.6%-5.8%
5Y2.6%10Y2.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.9%-13.3%+8.4%
TTM-3.1%-12.8%+9.7%
YOY2.8%-11.6%+14.4%
5Y2.6%-13.8%+16.4%
10Y2.6%-15.6%+18.2%
1.1.3. Return on Equity

Shows how efficient Genereach is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Genereach to the Biotechnology industry mean.
  • -7.0% Return on Equity means Genereach generated NT$-0.07 for each NT$1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of GeneReach Biotechnology:

  • The MRQ is -7.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -4.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.0%TTM-4.6%-2.4%
TTM-4.6%YOY4.4%-9.0%
TTM-4.6%5Y4.2%-8.8%
5Y4.2%10Y4.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.0%-16.9%+9.9%
TTM-4.6%-16.1%+11.5%
YOY4.4%-14.9%+19.3%
5Y4.2%-19.3%+23.5%
10Y4.2%-20.1%+24.3%

1.2. Operating Efficiency of GeneReach Biotechnology.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Genereach is operating .

  • Measures how much profit Genereach makes for each NT$1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Genereach to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated NT$0.00  for each NT$1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of GeneReach Biotechnology:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-40.5%+40.5%
TTM-40.5%YOY30.0%-70.5%
TTM-40.5%5Y16.8%-57.3%
5Y16.8%10Y16.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--298.0%+298.0%
TTM-40.5%-238.5%+198.0%
YOY30.0%-288.4%+318.4%
5Y16.8%-486.2%+503.0%
10Y16.8%-628.4%+645.2%
1.2.2. Operating Ratio

Measures how efficient Genereach is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 3.66 means that the operating costs are NT$3.66 for each NT$1 in net sales.

Let's take a look of the Operating Ratio trends of GeneReach Biotechnology:

  • The MRQ is 3.660. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.825. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.660TTM2.825+0.835
TTM2.825YOY1.299+1.526
TTM2.8255Y1.520+1.304
5Y1.52010Y1.5200.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.6603.235+0.425
TTM2.8253.310-0.485
YOY1.2993.838-2.539
5Y1.5205.679-4.159
10Y1.5207.823-6.303

1.3. Liquidity of GeneReach Biotechnology.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Genereach is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.07 means the company has NT$3.07 in assets for each NT$1 in short-term debts.

Let's take a look of the Current Ratio trends of GeneReach Biotechnology:

  • The MRQ is 3.070. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.127. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.070TTM3.127-0.057
TTM3.127YOY3.711-0.584
TTM3.1275Y3.488-0.361
5Y3.48810Y3.4880.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.0703.863-0.793
TTM3.1274.169-1.042
YOY3.7115.337-1.626
5Y3.4886.122-2.634
10Y3.4886.434-2.946
1.3.2. Quick Ratio

Measures if Genereach is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Genereach to the Biotechnology industry mean.
  • A Quick Ratio of 1.63 means the company can pay off NT$1.63 for each NT$1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of GeneReach Biotechnology:

  • The MRQ is 1.634. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 0.778. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ1.634TTM0.778+0.857
TTM0.778YOY0.525+0.252
TTM0.7785Y0.739+0.039
5Y0.73910Y0.7390.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6343.504-1.870
TTM0.7783.991-3.213
YOY0.5255.371-4.846
5Y0.7396.088-5.349
10Y0.7396.395-5.656

1.4. Solvency of GeneReach Biotechnology.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Genereach assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Genereach to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.27 means that Genereach assets are financed with 26.7% credit (debt) and the remaining percentage (100% - 26.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of GeneReach Biotechnology:

  • The MRQ is 0.267. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.291. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.267TTM0.291-0.025
TTM0.291YOY0.342-0.051
TTM0.2915Y0.318-0.027
5Y0.31810Y0.3180.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2670.339-0.072
TTM0.2910.337-0.046
YOY0.3420.271+0.071
5Y0.3180.368-0.050
10Y0.3180.388-0.070
1.4.2. Debt to Equity Ratio

Measures if Genereach is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Genereach to the Biotechnology industry mean.
  • A Debt to Equity ratio of 37.7% means that company has NT$0.38 debt for each NT$1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of GeneReach Biotechnology:

  • The MRQ is 0.377. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.432. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.377TTM0.432-0.055
TTM0.432YOY0.539-0.108
TTM0.4325Y0.492-0.061
5Y0.49210Y0.4920.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3770.392-0.015
TTM0.4320.403+0.029
YOY0.5390.335+0.204
5Y0.4920.427+0.065
10Y0.4920.461+0.031

2. Market Valuation of GeneReach Biotechnology

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every NT$1 in earnings Genereach generates.

  • Above 15 is considered overpriced but always compare Genereach to the Biotechnology industry mean.
  • A PE ratio of -9.73 means the investor is paying NT$-9.73 for every NT$1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of GeneReach Biotechnology:

  • The EOD is -7.884. Based on the earnings, the company is expensive. -2
  • The MRQ is -9.734. Based on the earnings, the company is expensive. -2
  • The TTM is -17.363. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.884MRQ-9.734+1.851
MRQ-9.734TTM-17.363+7.629
TTM-17.363YOY4.677-22.040
TTM-17.3635Y5.519-22.883
5Y5.51910Y5.5190.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.884-2.300-5.584
MRQ-9.734-2.656-7.078
TTM-17.363-2.718-14.645
YOY4.677-4.145+8.822
5Y5.519-6.258+11.777
10Y5.519-6.315+11.834
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of GeneReach Biotechnology:

  • The EOD is -18.288. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -22.581. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 42.055. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD-18.288MRQ-22.581+4.293
MRQ-22.581TTM42.055-64.636
TTM42.055YOY29.770+12.285
TTM42.0555Y35.301+6.754
5Y35.30110Y35.3010.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-18.288-2.974-15.314
MRQ-22.581-3.306-19.275
TTM42.055-3.508+45.563
YOY29.770-5.613+35.383
5Y35.301-8.378+43.679
10Y35.301-8.873+44.174
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Genereach is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.63 means the investor is paying NT$2.63 for each NT$1 in book value.

Let's take a look of the Price to Book Ratio trends of GeneReach Biotechnology:

  • The EOD is 2.129. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.628. Based on the equity, the company is underpriced. +1
  • The TTM is 2.813. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.129MRQ2.628-0.500
MRQ2.628TTM2.813-0.185
TTM2.813YOY3.669-0.856
TTM2.8135Y5.211-2.398
5Y5.21110Y5.2110.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.1291.914+0.215
MRQ2.6282.116+0.512
TTM2.8132.097+0.716
YOY3.6692.881+0.788
5Y5.2113.550+1.661
10Y5.2113.936+1.275
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of GeneReach Biotechnology compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.070-1.045-2%0.064-1784%1.072-200%1.072-200%
Book Value Per Share--15.01016.524-9%20.753-28%17.803-16%17.803-16%
Current Ratio--3.0703.127-2%3.711-17%3.488-12%3.488-12%
Debt To Asset Ratio--0.2670.291-8%0.342-22%0.318-16%0.318-16%
Debt To Equity Ratio--0.3770.432-13%0.539-30%0.492-23%0.492-23%
Dividend Per Share----0%-0%0.714-100%0.714-100%
Eps---1.013-0.723-29%1.029-198%0.754-234%0.754-234%
Free Cash Flow Per Share---0.437-0.287-34%1.361-132%0.843-152%0.843-152%
Free Cash Flow To Equity Per Share---0.437-0.330-24%1.282-134%0.911-148%0.911-148%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---5.448--------
Intrinsic Value_10Y_min---3.305--------
Intrinsic Value_1Y_max--2.777--------
Intrinsic Value_1Y_min--2.729--------
Intrinsic Value_3Y_max--5.810--------
Intrinsic Value_3Y_min--5.598--------
Intrinsic Value_5Y_max--5.791--------
Intrinsic Value_5Y_min--5.593--------
Market Cap1835783100.000-23%2266718100.0002691907300.000-16%4394100550.000-48%5124430308.943-56%5124430308.943-56%
Net Profit Margin---1.062-0.743-30%0.145-832%-0.016-98%-0.016-98%
Operating Margin----0.4050%0.300-100%0.168-100%0.168-100%
Operating Ratio--3.6602.825+30%1.299+182%1.520+141%1.520+141%
Pb Ratio2.129-23%2.6282.813-7%3.669-28%5.211-50%5.211-50%
Pe Ratio-7.884+19%-9.734-17.363+78%4.677-308%5.519-276%5.519-276%
Price Per Share31.950-23%39.45046.850-16%76.475-48%89.186-56%89.186-56%
Price To Free Cash Flow Ratio-18.288+19%-22.58142.055-154%29.770-176%35.301-164%35.301-164%
Price To Total Gains Ratio-29.861+19%-36.870-60.331+64%0.252-14744%-0.044-100%-0.044-100%
Quick Ratio--1.6340.778+110%0.525+211%0.739+121%0.739+121%
Return On Assets---0.049-0.031-37%0.028-275%0.026-287%0.026-287%
Return On Equity---0.070-0.046-34%0.044-258%0.042-268%0.042-268%
Total Gains Per Share---1.070-1.045-2%0.064-1784%1.787-160%1.787-160%
Usd Book Value--26476785.20029147454.950-9%36607762.175-28%31404089.150-16%31404089.150-16%
Usd Book Value Change Per Share---0.033-0.032-2%0.002-1784%0.033-200%0.033-200%
Usd Book Value Per Share--0.4610.507-9%0.637-28%0.547-16%0.547-16%
Usd Dividend Per Share----0%-0%0.022-100%0.022-100%
Usd Eps---0.031-0.022-29%0.032-198%0.023-234%0.023-234%
Usd Free Cash Flow---770416.500-506764.900-34%2400195.075-132%1486551.014-152%1486551.014-152%
Usd Free Cash Flow Per Share---0.013-0.009-34%0.042-132%0.026-152%0.026-152%
Usd Free Cash Flow To Equity Per Share---0.013-0.010-24%0.039-134%0.028-148%0.028-148%
Usd Market Cap56358541.170-23%69588245.67082641554.110-16%134898886.885-48%157320010.485-56%157320010.485-56%
Usd Price Per Share0.981-23%1.2111.438-16%2.348-48%2.738-56%2.738-56%
Usd Profit---1787200.500-1276122.250-29%1698761.475-205%1295925.943-238%1295925.943-238%
Usd Revenue--1683127.5001730405.500-3%5756380.475-71%5390862.986-69%5390862.986-69%
Usd Total Gains Per Share---0.033-0.032-2%0.002-1784%0.055-160%0.055-160%
 EOD+3 -5MRQTTM+7 -25YOY+7 -265Y+7 -2810Y+7 -28

3.2. Fundamental Score

Let's check the fundamental score of GeneReach Biotechnology based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-7.884
Price to Book Ratio (EOD)Between0-12.129
Net Profit Margin (MRQ)Greater than0-1.062
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.634
Current Ratio (MRQ)Greater than13.070
Debt to Asset Ratio (MRQ)Less than10.267
Debt to Equity Ratio (MRQ)Less than10.377
Return on Equity (MRQ)Greater than0.15-0.070
Return on Assets (MRQ)Greater than0.05-0.049
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of GeneReach Biotechnology based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.961
Ma 20Greater thanMa 5031.918
Ma 50Greater thanMa 10034.607
Ma 100Greater thanMa 20036.873
OpenGreater thanClose31.800
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Gross Profit  3,83316,33720,170-17,0473,12316,55919,682-35,073-15,391



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in TWD. All numbers in thousands.

Summary
Total Assets1,176,142
Total Liabilities313,706
Total Stockholder Equity832,062
 As reported
Total Liabilities 313,706
Total Stockholder Equity+ 832,062
Total Assets = 1,176,142

Assets

Total Assets1,176,142
Total Current Assets632,139
Long-term Assets544,003
Total Current Assets
Cash And Cash Equivalents 216,772
Short-term Investments 315,098
Net Receivables 21,424
Inventory 67,374
Other Current Assets 3,867
Total Current Assets  (as reported)632,139
Total Current Assets  (calculated)624,535
+/- 7,604
Long-term Assets
Property Plant Equipment 440,909
Long-term Assets Other 8,646
Long-term Assets  (as reported)544,003
Long-term Assets  (calculated)449,555
+/- 94,448

Liabilities & Shareholders' Equity

Total Current Liabilities205,904
Long-term Liabilities107,802
Total Stockholder Equity832,062
Total Current Liabilities
Short Long Term Debt 147,912
Accounts payable 567
Other Current Liabilities 6,152
Total Current Liabilities  (as reported)205,904
Total Current Liabilities  (calculated)154,631
+/- 51,273
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt109,126
Long-term Liabilities  (as reported)107,802
Long-term Liabilities  (calculated)109,126
+/- 1,324
Total Stockholder Equity
Retained Earnings 37,671
Total Stockholder Equity (as reported)832,062
Total Stockholder Equity (calculated)37,671
+/- 794,391
Other
Capital Stock574,575
Common Stock Shares Outstanding 57,458
Net Invested Capital 979,974
Net Working Capital 426,235
Property Plant and Equipment Gross 440,909



Balance Sheet

Currency in TWD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-30
> Total Assets 
1,091,560
1,240,506
1,325,601
1,454,614
1,736,761
1,684,418
1,816,383
1,933,897
1,886,075
1,621,901
1,531,076
1,475,070
1,208,397
1,176,142
1,176,1421,208,3971,475,0701,531,0761,621,9011,886,0751,933,8971,816,3831,684,4181,736,7611,454,6141,325,6011,240,5061,091,560
   > Total Current Assets 
645,280
798,642
889,268
967,974
1,197,993
1,180,538
1,288,990
1,397,151
1,349,896
1,070,075
977,371
920,759
698,900
632,139
632,139698,900920,759977,3711,070,0751,349,8961,397,1511,288,9901,180,5381,197,993967,974889,268798,642645,280
       Cash And Cash Equivalents 
275,517
313,680
387,059
354,808
586,149
663,434
779,806
811,396
952,892
748,614
691,523
409,890
494,215
216,772
216,772494,215409,890691,523748,614952,892811,396779,806663,434586,149354,808387,059313,680275,517
       Short-term Investments 
29,100
42,720
14,268
13,930
13,925
13,840
14,313
14,860
15,875
15,355
15,225
295,830
29,930
315,098
315,09829,930295,83015,22515,35515,87514,86014,31313,84013,92513,93014,26842,72029,100
       Net Receivables 
107,155
166,423
174,417
288,903
300,840
196,468
168,150
283,375
78,847
54,892
57,567
45,643
38,395
21,424
21,42438,39545,64357,56754,89278,847283,375168,150196,468300,840288,903174,417166,423107,155
       Inventory 
214,021
237,078
265,507
267,390
256,542
268,300
295,619
268,517
283,893
235,811
198,517
153,482
124,697
67,374
67,374124,697153,482198,517235,811283,893268,517295,619268,300256,542267,390265,507237,078214,021
       Other Current Assets 
36,460
50,060
20,891
18,226
17,986
17,659
18,485
18,211
21,235
5,674
19,897
20,834
4,025
3,867
3,8674,02520,83419,8975,67421,23518,21118,48517,65917,98618,22620,89150,06036,460
   > Long-term Assets 
446,280
441,864
436,333
486,640
538,768
503,880
527,393
536,746
536,179
551,826
552,770
554,311
509,497
544,003
544,003509,497554,311552,770551,826536,179536,746527,393503,880538,768486,640436,333441,864446,280
       Property Plant Equipment 
375,938
385,558
384,330
426,323
424,368
397,105
420,308
432,989
434,733
442,588
441,385
442,468
449,376
440,909
440,909449,376442,468441,385442,588434,733432,989420,308397,105424,368426,323384,330385,558375,938
       Other Assets 
47,032
37,416
36,720
43,560
98,066
93,510
94,219
90,616
92,659
0
102,411
107,636
0
0
00107,636102,411092,65990,61694,21993,51098,06643,56036,72037,41647,032
> Total Liabilities 
317,217
382,749
375,386
397,528
710,604
596,348
625,741
610,963
732,585
519,226
466,199
528,583
284,483
313,706
313,706284,483528,583466,199519,226732,585610,963625,741596,348710,604397,528375,386382,749317,217
   > Total Current Liabilities 
207,887
245,142
239,272
247,267
369,490
278,214
281,811
268,277
591,411
385,086
336,663
404,549
164,157
205,904
205,904164,157404,549336,663385,086591,411268,277281,811278,214369,490247,267239,272245,142207,887
       Short Long Term Debt 
69,708
70,398
68,097
93,574
70,227
81,327
73,849
77,844
264,085
265,962
259,357
261,580
101,104
147,912
147,912101,104261,580259,357265,962264,08577,84473,84981,32770,22793,57468,09770,39869,708
       Accounts payable 
53,755
31,688
45,869
58,398
27,939
31,677
31,846
36,047
16,987
806
7,701
8,086
1,135
567
5671,1358,0867,70180616,98736,04731,84631,67727,93958,39845,86931,68853,755
       Other Current Liabilities 
108,515
154,739
133,189
124,404
274,954
181,497
182,349
164,315
308,862
6,958
62,188
130,329
8,890
6,152
6,1528,890130,32962,1886,958308,862164,315182,349181,497274,954124,404133,189154,739108,515
   > Long-term Liabilities 
109,330
137,607
136,114
150,261
341,114
318,134
343,930
342,686
141,174
134,140
140,563
124,034
120,326
107,802
107,802120,326124,034140,563134,140141,174342,686343,930318,134341,114150,261136,114137,607109,330
       Capital Lease Obligations Min Short Term Debt
108,105
106,905
99,574
118,927
116,758
95,894
125,439
125,400
124,883
121,534
118,956
114,523
112,321
109,126
109,126112,321114,523118,956121,534124,883125,400125,43995,894116,758118,92799,574106,905108,105
       Long-term Liabilities Other 
484
57
57
57
57
20
20
20
20
20
20
20
20
20
20202020202020202057575757484
> Total Stockholder Equity
721,121
813,015
905,591
1,014,291
984,080
1,049,807
1,152,550
1,289,784
1,119,820
1,067,664
1,030,417
914,303
891,879
832,062
832,062891,879914,3031,030,4171,067,6641,119,8201,289,7841,152,5501,049,807984,0801,014,291905,591813,015721,121
   Common Stock
405,900
405,900
405,900
405,900
405,900
417,873
417,873
417,873
459,660
0
459,660
459,660
0
0
00459,660459,6600459,660417,873417,873417,873405,900405,900405,900405,900405,900
   Retained Earnings 
47,225
137,946
230,995
340,725
426,430
491,741
591,565
728,722
514,919
406,334
427,125
197,251
95,448
37,671
37,67195,448197,251427,125406,334514,919728,722591,565491,741426,430340,725230,995137,94647,225
   Accumulated Other Comprehensive Income 00000000000000
   Capital Surplus 00000000000000
   Treasury Stock00000000000000



Balance Sheet

Currency in TWD. All numbers in thousands.




Cash Flow

Currency in TWD. All numbers in thousands.




Income Statement

Currency in TWD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue225,460
Cost of Revenue-197,876
Gross Profit27,58427,584
 
Operating Income (+$)
Gross Profit27,584
Operating Expense-433,313
Operating Income-207,853-405,729
 
Operating Expense (+$)
Research Development61,458
Selling General Administrative173,979
Selling And Marketing Expenses0
Operating Expense433,313235,437
 
Net Interest Income (+$)
Interest Income14,472
Interest Expense-5,762
Other Finance Cost-0
Net Interest Income8,710
 
Pretax Income (+$)
Operating Income-207,853
Net Interest Income8,710
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-218,345-207,853
EBIT - interestExpense = -5,762
-166,270
-160,508
Interest Expense5,762
Earnings Before Interest and Taxes (EBIT)0-212,583
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-218,345
Tax Provision--47,993
Net Income From Continuing Ops-170,352-170,352
Net Income-166,270
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-8,710
 

Technical Analysis of Genereach
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Genereach. The general trend of Genereach is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Genereach's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of GeneReach Biotechnology.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 32.10 < 32.10 < 36.30.

The bearish price targets are: 29.20.

Tweet this
GeneReach Biotechnology Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of GeneReach Biotechnology. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

GeneReach Biotechnology Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of GeneReach Biotechnology. The current macd is -0.91765889.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Genereach price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Genereach. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Genereach price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
GeneReach Biotechnology Daily Moving Average Convergence/Divergence (MACD) ChartGeneReach Biotechnology Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of GeneReach Biotechnology. The current adx is 46.69.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Genereach shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
GeneReach Biotechnology Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of GeneReach Biotechnology. The current sar is 29.35.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
GeneReach Biotechnology Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of GeneReach Biotechnology. The current rsi is 43.96. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
GeneReach Biotechnology Daily Relative Strength Index (RSI) ChartGeneReach Biotechnology Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of GeneReach Biotechnology. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Genereach price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
GeneReach Biotechnology Daily Stochastic Oscillator ChartGeneReach Biotechnology Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of GeneReach Biotechnology. The current cci is -5.53824853.

GeneReach Biotechnology Daily Commodity Channel Index (CCI) ChartGeneReach Biotechnology Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of GeneReach Biotechnology. The current cmo is 4.24924394.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
GeneReach Biotechnology Daily Chande Momentum Oscillator (CMO) ChartGeneReach Biotechnology Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of GeneReach Biotechnology. The current willr is -26.66666667.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Genereach is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
GeneReach Biotechnology Daily Williams %R ChartGeneReach Biotechnology Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of GeneReach Biotechnology.

GeneReach Biotechnology Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of GeneReach Biotechnology. The current atr is 0.64584579.

GeneReach Biotechnology Daily Average True Range (ATR) ChartGeneReach Biotechnology Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of GeneReach Biotechnology. The current obv is -192,981,280.

GeneReach Biotechnology Daily On-Balance Volume (OBV) ChartGeneReach Biotechnology Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of GeneReach Biotechnology. The current mfi is 42.15.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
GeneReach Biotechnology Daily Money Flow Index (MFI) ChartGeneReach Biotechnology Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for GeneReach Biotechnology.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-24CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-16CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-06CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-29STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

GeneReach Biotechnology Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of GeneReach Biotechnology based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.961
Ma 20Greater thanMa 5031.918
Ma 50Greater thanMa 10034.607
Ma 100Greater thanMa 20036.873
OpenGreater thanClose31.800
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Genereach with someone you think should read this too:
  • Are you bullish or bearish on Genereach? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Genereach? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about GeneReach Biotechnology

I send you an email if I find something interesting about GeneReach Biotechnology.


Comments

How you think about this?

Leave a comment

Stay informed about GeneReach Biotechnology.

Receive notifications about GeneReach Biotechnology in your mailbox!